| scholarly article | Q13442814 |
| P50 | author | Marjorie Robert-Guroff | Q30651738 |
| P2093 | author name string | V S Kalyanaraman | |
| Bo Peng | |||
| George N Pavlakis | |||
| Joel Pinczewski | |||
| David Venzon | |||
| L Jean Patterson | |||
| Cindy Munch | |||
| Ersell Richardson | |||
| Kristine Aldrich | |||
| Melissa Leonard | |||
| Nina Malkevitch | |||
| Yuanmei Lou | |||
| P2860 | cites work | Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection | Q24645815 |
| Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome | Q24648628 | ||
| Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia | Q28254584 | ||
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes | Q29616210 | ||
| Importance of the nef gene for maintenance of high virus loads and for development of AIDS | Q29618369 | ||
| The conserved core of human immunodeficiency virus type 1 Nef is essential for association with Lck and for enhanced viral replication in T-lymphocytes | Q30175324 | ||
| Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants | Q30976921 | ||
| Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene | Q33196552 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. | Q33649657 | ||
| Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. | Q33782797 | ||
| Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. | Q33784777 | ||
| Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. | Q33786386 | ||
| Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef | Q33798199 | ||
| Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV | Q33800033 | ||
| Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. | Q33820014 | ||
| Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment | Q33847673 | ||
| Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors | Q33852720 | ||
| Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge | Q33852768 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen | Q33944652 | ||
| Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. | Q34069214 | ||
| Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine | Q34333402 | ||
| Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine | Q34339365 | ||
| Neutralizing antibodies against HIV -- back in the major leagues? | Q34712716 | ||
| Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene | Q34996554 | ||
| Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen | Q35155380 | ||
| An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge | Q35898573 | ||
| Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. | Q36368095 | ||
| Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant | Q36685348 | ||
| Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model | Q37164192 | ||
| Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model | Q40732241 | ||
| Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation | Q40777827 | ||
| Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice | Q40916152 | ||
| Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes | Q41471495 | ||
| Simultaneous Administration of Live, Enteric-Coated Adenovirus Types 4,7, and 21 Vaccines: Safety and Immunogenicity | Q41689230 | ||
| The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus | Q42629343 | ||
| Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. | Q43513973 | ||
| Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys | Q43871438 | ||
| Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. | Q44022556 | ||
| Vaccines. Monkey puzzles | Q44044879 | ||
| Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization | Q44592013 | ||
| Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses | Q45730388 | ||
| Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection | Q45732713 | ||
| Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope | Q45733017 | ||
| Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity | Q45734062 | ||
| An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants | Q45735721 | ||
| Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines | Q45737393 | ||
| Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
| Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques | Q45751494 | ||
| Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees | Q45776493 | ||
| Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration | Q45783638 | ||
| High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants | Q45850377 | ||
| Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes | Q57075675 | ||
| Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f | Q57075677 | ||
| A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in M | Q64377818 | ||
| Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs | Q64378362 | ||
| Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols | Q64379647 | ||
| A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge | Q64379721 | ||
| Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination | Q73097737 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Simian immunodeficiency virus | Q1890246 |
| P304 | page(s) | 8607-8620 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. | |
| P478 | volume | 77 |
| Q35851801 | A call for replicating vector prime-protein boost strategies in HIV vaccine design |
| Q35785031 | A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe |
| Q35675044 | Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus |
| Q36667821 | Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS |
| Q45416216 | Assembly of pseudorabies virus genome-based transfer vehicle carrying major antigen sites of S gene of transmissible gastroenteritis virus: potential perspective for developing live vector vaccines |
| Q37742680 | Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection. |
| Q34600955 | Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial |
| Q45399692 | Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). |
| Q36961218 | Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection |
| Q33872445 | Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains |
| Q37347813 | Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. |
| Q37033311 | Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques |
| Q64377680 | Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses |
| Q61641083 | Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag |
| Q45395627 | Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats |
| Q35032794 | HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques |
| Q30432382 | Human immunodeficiency virus vaccine an update |
| Q45411816 | Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. |
| Q34260720 | Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine |
| Q37096865 | Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques |
| Q45398545 | Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus |
| Q35826525 | Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 va |
| Q55237722 | Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus. |
| Q40481125 | Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. |
| Q36954239 | Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting |
| Q34574409 | Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge |
| Q38096489 | Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets |
| Q64376800 | Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques |
| Q56993265 | Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development |
| Q35940685 | Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route |
| Q36464587 | Replicating and non-replicating viral vectors for vaccine development |
| Q33911986 | Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies |
| Q36949703 | Sequential priming with simian immunodeficiency virus (SIV) DNA vaccines, with or without encoded cytokines, and a replicating adenovirus-SIV recombinant followed by protein boosting does not control a pathogenic SIVmac251 mucosal challenge |
| Q37297052 | Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge |
| Q52592228 | Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. |
Search more.